文献速递临床试验与 GCP流行病学与生物统计

BILITE:联合建模纵向免疫反应与生存时间的贝叶斯随机II期免疫治疗设计

BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy.
PubMed 文献 · Stat Med · 2020-08-27

针对免疫治疗中免疫反应与部分患者长期持久缓解的特点,提出双臂贝叶斯自适应随机II期设计BILITE,联合建模纵向免疫反应与时间-事件疗效,并假设部分患者被治愈。模拟研究显示,与忽略免疫反应的传统设计相比,BILITE在识别有前景药物和因无效提前终止试验方面表现更优。

要点

  • BILITE采用贝叶斯自适应随机II期设计,联合建模纵向免疫反应与时间-事件疗效。
  • 设计假设部分患者被治疗治愈,并用效用函数量化治疗可取性。
  • 模拟研究显示BILITE在识别 promising 药物和因无效提前终止方面优于传统设计。

核心结论

  • BILITE设计在识别有前景药物和因无效提前终止试验方面优于忽略免疫反应的传统设计。

研究设计与样本

  • 提出双臂贝叶斯自适应随机II期临床试验设计,联合建模纵向免疫反应与时间-事件疗效。
  • 纵向免疫反应采用分层非线性混合效应模型,治愈组与易感组轨迹模式可不同。
  • 易感组的时间-事件疗效数据在给定免疫反应轨迹下采用时间依赖Cox型回归模型。
  • 采用两阶段设计自适应随机分配患者并在试验结束时做出治疗推荐。

主要发现

  • 模拟研究表明BILITE在识别有前景药物和因无效提前终止试验的操作特性上优于传统设计。

临床怎么用

  • 可用于免疫治疗II期临床试验中联合评估纵向免疫反应与时间-事件疗效并自适应随机分组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy-treatments that target a patient's immune system-has attracted considerable attention in cancer research. Its recent success has led to generation of novel immunotherapeutic agents that need to be evaluated in clinical trials. Two unique features of immunotherapy are the immune response and the fact that some patients may achieve long-term durable response. In this article, we propose a two-arm Bayesian adaptive randomized phase II clinical trial design for immunotherapy that jointly models the longitudinal immune response and time-to-event efficacy (BILITE), with a fraction of patients assumed to be cured by the treatment. The longitudinal immune response is modeled using hierarchical nonlinear mixed-effects models with possibly different trajectory patterns for the cured and susceptible groups. Conditional on the immune response trajectory, the time-to-event efficacy data for patients in the susceptible group is modeled via a time-dependent Cox-type regression model. We quantify the desirability of the treatment using a utility function and propose a two-stage design to adaptively randomize patients to treatments and make treatment recommendations at the end of the trial. Simulation studies show that compared with a conventional design that ignores the immune response, BILITE yields superior operating characteristics in terms of the ability to identify promising agents and terminate the trial early for futility.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Guo B, Zang Y. BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy. Stat Med. 2020. PMID: 32854145. doi:10.1002/sim.8733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。